Join Growin Stock Community!

聖安生醫6926.TW Overview

TW StockBiotech. & Medical
(No presentation for 6926)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

聖安生醫（6926）Overall Performance

聖安生醫（6926）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

聖安生醫（6926） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

聖安生醫（6926）Key Information

聖安生醫（6926）Profile

Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. The company was founded in 2021 and is based in Taichung, Taiwan.

聖安生醫（6926）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.77
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
357.13
PB Ratio
3.50
Price-to-FCF
200.11
METRIC
VALUE
vs. INDUSTRY
Gross Margin
70.00%
Net Margin
-1972.96%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.77
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
357.13
PB Ratio
3.50
Price-to-FCF
200.11
Gross Margin
70.00%
Net Margin
-1972.96%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6926

聖安生醫

68.30D

1.76%

(0.02)

  • When is 6926's latest earnings report released?

    The most recent financial report for 聖安生醫 (6926) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6926's short-term business performance and financial health. For the latest updates on 6926's earnings releases, visit this page regularly.

  • How much cash does 6926 have?

    At the end of the period, 聖安生醫 (6926) held Total Cash and Cash Equivalents of 20.63M, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6926's EPS continuing to grow?

    According to the past four quarterly reports, 聖安生醫 (6926)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6926?

    聖安生醫 (6926)'s Free Cash Flow (FCF) for the period is 3.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 309.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.